Mariana Brandao: My comment on the ARTEMIDE-01 phase I trial testing a new bispecific anti-PD-1/anti-TIGIT antibody called Rilvegostomig

Mariana Brandao, a Medical Oncologist at Institut Jules Bordet, recently shared on LinkedIn:

“Here’s my comment on the ARTEMIDE-01 phase I trial (NCT049955230) testing a new bispecific anti-PD-1/anti-TIGIT antibody called Rilvegostomig, presented at ESMO23.
We showed the efficacy and safety data on the population of patients with advanced NSCLC that had previously been treated with immune checkpoint inhibitors (parts A + B):
>> n=83, ORR of only 6%, but a 6-month disease-control rate of 31%, with an excelent toxicity profile!
Parts C+D, including patients with treatment-naive NSCLC, is now recruiting!”

For details click here.
Source: Mariana Brandao/LinkedIn